Amedisys Reports Second Quarter 2022 Financial Results and Updates 2022 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
Amedisys (AMED) Tops Q2 EPS by 24c
July 27, 2022 4:15 PM EDTAmedisys (NASDAQ: AMED) reported Q2 EPS of $1.47, $0.24 better than the analyst estimate of $1.23. Revenue for the quarter came in at $557.9 million versus the consensus estimate of $583.12 million.
GUIDANCE:
Amedisys sees FY2022 revenue of $2.29-2.31 billion, versus the consensus of $2.35... More
